CN113087671B - 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 - Google Patents
一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 Download PDFInfo
- Publication number
- CN113087671B CN113087671B CN202011516692.7A CN202011516692A CN113087671B CN 113087671 B CN113087671 B CN 113087671B CN 202011516692 A CN202011516692 A CN 202011516692A CN 113087671 B CN113087671 B CN 113087671B
- Authority
- CN
- China
- Prior art keywords
- methyl
- ethyl
- cancer
- hydroxy
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Cyano-substituted pyridine Chemical class 0.000 title claims abstract description 364
- 238000002360 preparation method Methods 0.000 title abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 115
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims abstract description 49
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims abstract description 49
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 89
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 87
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 44
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 44
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 25
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 25
- 125000006232 ethoxy propyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 24
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 24
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 19
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 17
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 claims description 16
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 15
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 15
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 14
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 claims description 10
- 125000004373 methylthiopropyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims description 9
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000006229 isopropoxyethyl group Chemical group [H]C([H])([H])C([H])(OC([H])([H])C([H])([H])*)C([H])([H])[H] 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 125000003566 oxetanyl group Chemical group 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 201000009036 biliary tract cancer Diseases 0.000 claims description 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 17
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 13
- 102000020233 phosphotransferase Human genes 0.000 abstract description 13
- 239000000651 prodrug Substances 0.000 abstract description 9
- 229940002612 prodrug Drugs 0.000 abstract description 9
- 239000012453 solvate Substances 0.000 abstract description 8
- 150000004677 hydrates Chemical class 0.000 abstract description 5
- 229940043355 kinase inhibitor Drugs 0.000 abstract description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 28
- 108091008794 FGF receptors Proteins 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 26
- 239000003112 inhibitor Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 239000000543 intermediate Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 13
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- 150000003384 small molecules Chemical class 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000003419 tautomerization reaction Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical group ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 239000012265 solid product Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 5
- 102100020683 Beta-klotho Human genes 0.000 description 5
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 5
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 5
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 4
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 4
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 4
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 4
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 4
- MBWRLLRCTIYXDW-UHFFFAOYSA-N N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound ClC1=C(C(=C(C=C1OC)OC)Cl)NC(N(C)C1=CC(=NC=N1)NC1=C(C=C(C=C1)N1CCN(CC1)CC)NC(C=C)=O)=O MBWRLLRCTIYXDW-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 3
- PZOZYLSYQJYXBI-UHFFFAOYSA-N 2-propan-2-yloxyaniline Chemical compound CC(C)OC1=CC=CC=C1N PZOZYLSYQJYXBI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 229950004444 erdafitinib Drugs 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 2
- AEILWAMPVYDQHK-UHFFFAOYSA-N 2-chloro-4-(2-propan-2-yloxyanilino)pyrimidine-5-carbonitrile Chemical compound CC(C)OC1=CC=CC=C1NC2=NC(=NC=C2C#N)Cl AEILWAMPVYDQHK-UHFFFAOYSA-N 0.000 description 2
- PEDMFCHWOVJDNW-UHFFFAOYSA-N 5-fluoro-2-nitroaniline Chemical compound NC1=CC(F)=CC=C1[N+]([O-])=O PEDMFCHWOVJDNW-UHFFFAOYSA-N 0.000 description 2
- OTXRSWDXINWNGA-UHFFFAOYSA-N 6-chloro-4-(2-propan-2-yloxyanilino)pyridine-3-carbonitrile Chemical compound CC(C)OC1=CC=CC=C1NC2=CC(=NC=C2C#N)Cl OTXRSWDXINWNGA-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BEMNJULZEQTDJY-UHFFFAOYSA-N [5-amino-1-(2-methyl-3h-benzimidazol-5-yl)pyrazol-4-yl]-(1h-indol-2-yl)methanone Chemical compound C1=CC=C2NC(C(=O)C=3C=NN(C=3N)C=3C=C4N=C(NC4=CC=3)C)=CC2=C1 BEMNJULZEQTDJY-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000005496 eutectics Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- MGZKYOAQVGSSGC-DLBZAZTESA-N fisogatinib Chemical compound COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1 MGZKYOAQVGSSGC-DLBZAZTESA-N 0.000 description 2
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229940127084 other anti-cancer agent Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000004537 pulping Methods 0.000 description 2
- QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical group CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- FFMQJSXRJPHACJ-UHFFFAOYSA-N tert-butyl n-(5-fluoro-2-nitrophenyl)-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)C1=CC(F)=CC=C1[N+]([O-])=O FFMQJSXRJPHACJ-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- KPJDVVCDVBFRMU-AREMUKBSSA-N (6r)-6-(2-fluorophenyl)-n-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine Chemical compound COCCNCCC1=CC=CC(NC=2N=C3C4=CC=CC=C4[C@H](C=4C(=CC=CC=4)F)CC3=CN=2)=C1 KPJDVVCDVBFRMU-AREMUKBSSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- KFHQOZXAFUKFNB-UHFFFAOYSA-N 1,3-oxathiolanyl Chemical group [CH]1OCCS1 KFHQOZXAFUKFNB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- KEIPNCCJPRMIAX-HNNXBMFYSA-N 1-[(3s)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC(C#CC=2C3=C(N)N=CN=C3N([C@@H]3CN(CC3)C(=O)C=C)N=2)=C1 KEIPNCCJPRMIAX-HNNXBMFYSA-N 0.000 description 1
- MBDUIEKYVPVZJH-UHFFFAOYSA-N 1-ethylsulfonylethane Chemical group CCS(=O)(=O)CC MBDUIEKYVPVZJH-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
- OACCNUGECQQVLB-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=C(Cl)N=C1Cl OACCNUGECQQVLB-UHFFFAOYSA-N 0.000 description 1
- VDZZYOJYLLNBTD-UHFFFAOYSA-N 2-[4-[[5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidin-2-yl]amino]pyrazol-1-yl]ethanol Chemical compound COC1=CC(OC)=C(F)C(COC=2C=NC(NC3=CN(CCO)N=C3)=NC=2)=C1F VDZZYOJYLLNBTD-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HNLRRJSKGXOYNO-UHFFFAOYSA-N 4-[[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl]piperazin-2-one Chemical compound N12N=CN=C(N)C2=C(C=2SC3=C(OC)C=C(C)C=C3C=2)C(COC)=C1CN1CCNC(=O)C1 HNLRRJSKGXOYNO-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- IBHOLSBDZMIPPT-UHFFFAOYSA-N 5-[2-[[4-[1-(2-hydroxyethyl)piperidin-4-yl]benzoyl]amino]pyridin-4-yl]oxy-6-(2-methoxyethoxy)-n-methylindole-1-carboxamide Chemical compound COCCOC=1C=C2N(C(=O)NC)C=CC2=CC=1OC(C=1)=CC=NC=1NC(=O)C(C=C1)=CC=C1C1CCN(CCO)CC1 IBHOLSBDZMIPPT-UHFFFAOYSA-N 0.000 description 1
- PUIXMSRTTHLNKI-UHFFFAOYSA-N 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-(4-prop-2-enoylpiperazin-1-yl)propyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound C(C=C)(=O)N1CCN(CC1)CCCN1C(C(=CC2=C1N=C(N=C2)NC)C2=C(C(=CC(=C2Cl)OC)OC)Cl)=O PUIXMSRTTHLNKI-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 description 1
- 101710104526 Beta-klotho Proteins 0.000 description 1
- GRVJYIMAEYDVAV-UHFFFAOYSA-N CC(C)(C)C1=CC(N(CC2)CCC2N(C)C)=CC(OC(N)=O)=C1N Chemical compound CC(C)(C)C1=CC(N(CC2)CCC2N(C)C)=CC(OC(N)=O)=C1N GRVJYIMAEYDVAV-UHFFFAOYSA-N 0.000 description 1
- OJIWHOJJHMUGIP-UHFFFAOYSA-N CC(C)(C)C1=CC(N2CCN(C)CC2)=CC(OC(N)=O)=C1N Chemical compound CC(C)(C)C1=CC(N2CCN(C)CC2)=CC(OC(N)=O)=C1N OJIWHOJJHMUGIP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229940125407 FGF401 Drugs 0.000 description 1
- 101150082429 FGFR4 gene Proteins 0.000 description 1
- 229940125408 FGFR4 inhibitor Drugs 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100334745 Mus musculus Fgfr4 gene Proteins 0.000 description 1
- DQJRFNFUQKZFIU-UHFFFAOYSA-N N-[2-[[5-cyano-4-(2-propan-2-yloxyanilino)pyrimidin-2-yl]amino]-5-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound CC(C)OC1=CC=CC=C1NC2=NC(=NC=C2C#N)NC3=C(C=C(C=C3)N4CCN(CC4)C)NC(=O)C=C DQJRFNFUQKZFIU-UHFFFAOYSA-N 0.000 description 1
- BHKDKKZMPODMIQ-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N BHKDKKZMPODMIQ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940125828 TAS-120 Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 101710112793 Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001448 anilines Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000005612 glucoheptonate group Chemical group 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- TXEBNKKOLVBTFK-UHFFFAOYSA-N n-[2-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl]amino]-3-methylphenyl]prop-2-enamide Chemical compound COC1=CC(OC)=C(Cl)C(C=2C=C3C=NC(NC=4C(=CC=CC=4C)NC(=O)C=C)=NC3=CC=2)=C1Cl TXEBNKKOLVBTFK-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000000711 polarimetry Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical class C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- HVWZLJFPUZTJKZ-UHFFFAOYSA-N tert-butyl N-[2-amino-5-(4-ethylpiperazin-1-yl)phenyl]carbamate Chemical compound C1CN(CC)CCN1C1=CC=C(N)C(NC(=O)OC(C)(C)C)=C1 HVWZLJFPUZTJKZ-UHFFFAOYSA-N 0.000 description 1
- FCQZFLPCSSCYIJ-UHFFFAOYSA-N tert-butyl N-[5-(4-ethylpiperazin-1-yl)-2-nitrophenyl]carbamate Chemical compound C1CN(CC)CCN1C1=CC=C([N+]([O-])=O)C(NC(=O)OC(C)(C)C)=C1 FCQZFLPCSSCYIJ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用,具体涉及式(I)所示化合物、其异构体、水合物、溶剂化物、其药学上可接受的盐及其前药,其制备方法及其在制备作为激酶抑制剂的药物中的应用。本发明化合物对FGFR4及突变型FGFR4V550L等激酶均具有良好的抑制活性。
Description
技术领域
本发明涉及一种氰基取代吡啶及氰基取代嘧啶类化合物,其药学上可接受的盐,异构体,水合物,溶剂化物,或前药,及其制备方法和用途。
背景技术
细胞中FGFR的激活突变或扩增可导致FGF-FGFR信号通路的过度激活,使得细胞获得过度增殖、逃避凋亡、容易迁移等致癌特性,所以FGFRs可作为直接或间接肿瘤治疗的靶标。FGFR主要分为4种亚型,分别为FGFR1、FGFR2、FGFR3和FGFR4。各亚型均具有受体酪氨酸激酶的一般结构特点:与配体结合的胞外区、跨膜区和受体磷酸化的胞内区。当配体与受体特异性结合后,诱导FGFR自身磷酸化,进而二聚化,使得其结构域从非活性状态转变为活性状态。活化的FGFR又与胞内的激酶互相靠近,相互磷酸化,从而激活下游一系列的相关信号通路,最终刺激细胞的增殖、分化,抑制细胞凋亡。由于FGFR在肿瘤的发生发展中有重要的作用,针对FGFR的靶向治疗成为临床研究的热点领域。已有的靶向FGFR的药物,按照其来源可分为两类:第一类是化学小分子抑制剂,它可以竞争性或非竞争性的与FGFR胞内激酶结构域结合,抑制FGFR的自身磷酸化、二聚化和催化下游蛋白磷酸化的能力,从而抑制FGFR信号通路。第二类是生物单抗或多肽抑制剂,它可以与FGFR的胞外区结合,阻止FGF与FGFR的结合,从而抑制FGFR的活化,阻断FGFR信号的转导(Seiji Mori,Yoshikazu Takada,Med.Sci.2013,1,20-36)。
小分子酪氨酸激酶抑制剂通过阻断胞内激酶与ATP结合的活性,阻断细胞增殖信号。由于FGFR1、FGFR2、FGFR3激酶域的结构相似,现阶段研发的针对这三个激酶的抑制剂效果相差不大,然而,FGFR4激酶域与FGFR1-3激酶域存在一定差异,因此许多能有效抑制FGFR1-3的抑制剂对FGFR4效果不佳。如近几年处于临床试验阶段的AZD-4547、Infigratinib、CH-5183284、E-7090、BAY-1163877、INCB-54828等针对的是FGFR1/2/3靶标,FGF-401、BLU-554针对的是FGFR4靶标。小分子FGFR抑制剂可分为:1)ATP竞争性可逆抑制剂、2)共价结合不可逆抑制剂、3)ATP非竞争性抑制剂(伍代朝等,肿瘤防治研究2017,44(1):61-65)。
AZD-4547是与FGFR作用呈直线型的小分子选择性ATP竞争性可逆抑制剂。从FGFR1/AZD-4547的蛋白-配体复合物共晶结构可以看出,AZD-4547的3-氨基吡唑母环与铰链区的Ala564和Glu562有3个氢键作用,3,5-二甲氧基苯基侧链伸入铰链区向内的疏水口袋,对位手性哌嗪取代的苯甲酰基,与伸向铰链区外的近溶剂端结构域发生亲水或疏水的相互作用。在这些作用下,整个分子呈一种直线形式插入FGFR1的ATP结合区域,与FGFR1蛋白紧密结合。具有类似直线型作用的化合物还包括BGJ-398、CH-5183284和ASP-5878。
JNJ-42756493与FGFR作用呈T型的小分子选择性ATP竞争性可逆抑制剂,从JNJ-42756493/FGFR1共晶结构可以看出,JNJ-42756493的喹喔啉母环1位N与铰链区的Ala564形成一个氢键,3,5-二甲氧基苯基侧链占据铰链区向里的疏水口袋,而异丙胺侧链与铰链区向下的口袋有亲水或疏水的作用,异丙胺的NH与Asp641也有一个氢键作用。
由于蛋白ATP结合位点的铰链区与FGFR1、2和3有1个不同的半胱氨酸残基,而此位点FGFR1、2和3为酪氨酸残基。从这个结构上的微小差异出发,发现具有纳摩尔级抑制活性的FGFR选择性抑制剂PD173074,在此基础上发现了可特异性抑制FGFR4的2-氨基喹唑啉类衍生物,当氨基的β位上引入1个丙烯酰胺的取代基时获得化合物BLU-9931,发现其丙烯酰胺可与FGFR4的Cys552产生不可逆的共价结合,其对FGFR4抑制活性IC50为3nmol/L,其选择性比FGFR1/2/3分别高297、184和50倍。通过对BLU-9931的进一步结构优化,发现BLU-554是选择性FGFR4共价不可逆抑制剂,并于2015年9月获得了FDA批准用于治疗肝细胞癌的临床试验。TAS-120和PRN-1371也是FGFR共价抑制剂,对FGFR各亚型的酶抑制活性均可达到纳摩尔水平。
ARQ-087为非ATP竞争性的抑制剂,其对FGFR1、2和3的选择性比FGFR4有8倍以上的优势。
FGFR的改变已与多种人类癌症相关联,包括骨髓瘤、乳腺癌、胃癌、结肠癌、膀胱癌、胰腺癌及肝细胞癌。FGFR的小分子抑制剂可分为泛FGFR和FGFR4特异性小分子抑制剂。由于FGFR1、FGFR2、FGFR3激酶域的结构相似,现阶段研发的针对这三个激酶的抑制剂效果相差不大。据报导FGFR4尤其在肝癌中起重要作用(PLoS One,2012,第7卷,36713)。FGFR4激酶域与FGFR1-3激酶域存在一定差异,因此许多能有效抑制FGFR1-3的抑制剂对FGFR4效果不佳。
为了提高小分子抑制剂对FGFR4激酶域的选择性并减少不良反应,H3生物医药公司在专利WO 2015057938 A1(公开日:20150423)Pyrimidines as FGFR4 inhibitors andtheir preparation和WO 2015057963 A1(公开日:20150423)N-Aryl-heteroarylaminesas FGFR4 inhibitors and their preparation中公开了FGFR4特异性抑制剂,其中H3B-6527已进入FDA一期临床阶段,并获得孤儿药资格,其结构如下:
H3B6527对FGF19基因扩增的细胞具有强抗肿瘤活性,且在小鼠和猴的动物模型中没有胆汁酸相关的不良反应。但是H3B-6527单一给药仅控制癌细胞生长而无法清除癌细胞(Cancer Res;77(24)December 15,2017)。H3B-6527对关键位点V550L或V550突变导致的耐药性使疗效降低或失效,如何突破这些导致耐药的基因突变的限制将成为下一阶段FGFR4抑制剂研究的重点。
针对FGFR4靶标的抑制剂有许多优点,尤其是其优异的选择性和抗突变性。目前上市的药物很少,因此,发现这类以FGFR4为靶标的小分子抑制剂会有更好的治疗效果和应用前景。研发出全新的、对FGFR4高选择性的、药效强的抑制剂成为临床中亟待解决的问题。
发明内容
本发明所提供式(I)表示的化合物,其药学上可接受的盐,异构体,水合物,溶剂化物,或前药,其可用作治疗或预防由酪氨酸激酶FGFR4引起的疾病,包括酪氨酸激酶FGFR4受体的某些变种。
式(I)中,
X为N或CH;
R2为氢、卤素、C1-C3烷氧基、C1-C3烷基;
R3选自氢、卤素、羟基、氨基、氰基、羧基、C1-C6烷基、卤代C1-C6烷基、卤代C1-C3烷氧基、C3-C6环烷基、C2-C3炔基、C2-C3烯基、C1-C3烷氧基、C1-C3烷硫基、单或双C1-C3烷基氨基、C3-C4环烷基氧基、C3-C4环烷基取代的C1-C3烷基、氰基取代的C1-C3烷基、氨基甲酰基取代的C1-C3烷基、或以下基团:
q为1-3的整数,
Rs选自-H、C1-C3烷基,Rp选自-H、C1-C3烷基,
R'、R”分别独立地为-H、C1-C3烷基、C3-C4环烷基,
R7选自-H、卤素、羟基、氰基、氨基、羧基、C1-C3烷基、C3-C4环烷基、C1-C3烷氧基、单或双C1-C3烷基取代的氨基;
R4为-T1-R8或-T2-R9,
p1为0-4的整数,p2为2-4的整数,p3为0-1的整数,
Rp为-H或C1-C3烷基,
R8选自-H、卤素、羟基、氨基、氰基、C1-C6烷基、卤代C1-C6烷基、卤代C1-C3烷氧基、C3-C6环烷基、C1-C3烷氧基、C1-C3烷硫基、单或双C1-C3烷基氨基、或者被1-2个选自羟基、C1-C6烷基、C1-C3烷氧基、甲酰基、乙酰基、丙酰基、异丙酰基、羟基取代的C1-C3烷基、羧基取代的C1-C3烷基、氧代、C1-C3烷基取代或非取代的4-6元杂脂环基、或-NR10R11中的相同或不同的取代基所取代或非取代的4-6元杂脂环基,
R10、R11各自独立地选自-H、C1-C6烷基、C3-C4环烷基、羟基取代的C2-C6烷基、氰基取代的C1-C2烷基、C1-C3烷氧基取代的C1-C3烷基、C1-C3烷硫基取代的C1-C3烷基、卤代C1-C3烷基、甲砜基取代C1-C3烷基、单或双C1-C3烷氨基取代C1-C3烷基、C1-C3烷基取代或非取代的4-6元杂脂环基,或者R10、R11与其相连的氮原子构成被1-2个选自-H、羟基、氧代、卤素、C1-C3烷氧基取代C1-C3烷基、C1-C3烷基砜基、氰基、氨基、C1-C3酰基、C1-C3烷基、单或双C1-C3烷氨基、羟基取代的C2-C3烷基、C1-C3烷氧基中的相同或不同的取代基所取代或非取代的4-6元杂脂环基,
所述4-6元杂脂环基含1-2个选自N、O或S的杂原子;
R9选自-H、C1-C6烷基、C3-C6环烷基、被1-2个选自羟基、C1-C3烷基、C1-C3烷氧基、甲酰基、乙酰基、丙酰基、异丙酰基中的相同或不同的取代基所取代或者非取代的4-6元杂脂环基,
R9中所述4-6元杂脂环基中含1-2个选自N、O或S的杂原子;
在优选的方案中,R2为-H、-F、-Cl、甲基或甲氧基。
在优选的方案中,R3选自-H、-F、-Cl、-Br、羟基、羧基、氰基、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、丙氧基、异丙氧基、环丙基氧基、环丁基氧基、甲硫基、乙硫基、丙硫基、异丙硫基、氟甲基、二氟甲基、三氟甲基、氟甲氧基、二氟甲氧基、三氟甲氧基、乙炔基、乙烯基、环丙基、环丁基、环丙基甲基、环丁基甲基、氨基、甲氨基、乙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基、或以下基团:
q为2-3的整数,
Rs选自-H、甲基、乙基,Rp选自-H、甲基、乙基,
R'、R”分别独立的选自-H、甲基、乙基、丙基、异丙基、环丙基、环丁基,
R7选自-H、-F、羟基、氰基、羧基、氨基、甲基、乙基、丙基、异丙基、甲氧基、乙氧基、丙氧基、异丙氧基、甲氨基、乙氨基、二甲氨基。
在进一步的优选方案中,R3选自-H、-F、-Cl、羟基、羧基、氰基、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、丙氧基、异丙氧基、环丙基氧基、环丁基氧基、甲硫基、乙硫基、丙硫基、异丙硫基、氟甲基、二氟甲基、三氟甲基、环丙基、环丁基、环丙基甲基、环丁基甲基、氨基、甲氨基、乙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基、甲氧基乙氧基、乙氧基乙氧基、氨基甲酰基(NH2CO-)、甲砜基。
在优选的方案中,R4为-T1-R8,
p1为0-3的整数,p2为2-3的整数;
Rp选自-H、甲基、乙基;
R8选自-H、F、-Cl、羟基、氨基、氰基、氟甲氧基、二氟甲氧基、三氟甲氧基、甲基、乙基、丙基、丁基、己基、异丙基、氟甲基、二氟甲基、三氟甲基、环丙基、环丁基、环戊基、环己基、甲氧基、乙氧基、丙氧基、丁氧基、异丙氧基、甲硫基、乙硫基、丙硫基、异丙硫基、甲氨基、乙氨基、丙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基或以下基团:
R12为-H、-F、甲基、乙基,
R13为-H、-F、羟基、羟甲基、氰基、甲基、乙基、甲氧基、或–NR15R16,
Rs1、Rs2分别独立地选自H、甲基;
R15、R16分别独立地为-H、甲基、乙基、丙基、异丙基、羟乙基、羟丙基、氰基甲基、氰基乙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、异丙氧基乙基、异丙氧基丙基、环丙基、环丁基、二甲氨基乙基、二甲氨基丙基、二乙氨基乙基、二乙氨基丙基、甲基乙基氨基乙基、甲基乙基氨基丙基、氟乙基、氟丙基、甲硫基乙基、甲硫基丙基、乙硫基乙基、乙硫基丙基、异丙硫基乙基、异丙硫基丙基、甲砜基乙基、甲砜基丙基、乙砜基乙基、乙砜基丙基、2-羟基-2-甲基丙基、3-羟基-3-甲基丁基、氧杂环丁基、四氢呋喃基、四氢吡喃基,或者R15、R16与其相连的氮原子构成取代或非取代的4-6元杂脂环基,选自以下基团:
R18选自-H、甲基、乙基、甲酰基、乙酰基、羟乙基、羟丙基、氟乙基、氟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基,
R19和R20各自独立地选自-H、甲基、乙基、羟基、氰基、氟、甲酰基、乙酰基、羟乙基、羟丙基、氟乙基、氟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基、氨基、甲氨基、二甲氨基、甲氧基、乙氧基。
在进一步的优选方案中,R4为-T1-R8,
p1为0,p2为2-3的整数;
Rp选自-H、甲基、乙基;
R8选自甲氨基、乙氨基、丙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基或以下基团:
R12为-H、-F、甲基、乙基,
R13为-H、-NR15R16,
Rs1、Rs2分别独立地选自H、甲基;
R15、R16分别独立地为-H、甲基、乙基、丙基、异丙基、羟乙基、羟丙基、氰基甲基、氰基乙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、异丙氧基乙基、异丙氧基丙基、环丙基、环丁基、二甲氨基乙基、二甲氨基丙基、二乙氨基乙基、二乙氨基丙基、甲基乙基氨基乙基、甲基乙基氨基丙基、氟乙基、氟丙基、甲硫基乙基、甲硫基丙基、乙硫基乙基、乙硫基丙基、异丙硫基乙基、异丙硫基丙基、甲砜基乙基、甲砜基丙基、乙砜基乙基、乙砜基丙基、2-羟基-2-甲基丙基、3-羟基-3-甲基丁基、氧杂环丁-3-基、四氢呋喃-3-基、四氢-2H-吡喃-4-基,或者R15、R16与其相连的氮原子构成取代或非取代的4-6元杂脂环基,选自以下基团:
R18选自-H、甲基、乙基、甲酰基、乙酰基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基,
R19和R20各自独立地选自-H、甲基、乙基、羟基、氰基、氟、羟乙基、羟丙基、氟乙基、氟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基、氨基、甲氨基、二甲氨基、甲氧基、乙氧基。
R12为-H、-F、甲基、乙基,
R13为-H、-NR15R16,
Rs1、Rs2为H,
R15、R16分别独立地为-H、甲基、乙基、丙基、异丙基、羟乙基、羟丙基、氰基甲基、氰基乙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、异丙氧基乙基、异丙氧基丙基、环丙基、环丁基、二甲氨基乙基、二甲氨基丙基、二乙氨基乙基、二乙氨基丙基、甲基乙基氨基乙基、甲基乙基氨基丙基、氟乙基、氟丙基、甲硫基乙基、甲硫基丙基、乙硫基乙基、乙硫基丙基、异丙硫基乙基、异丙硫基丙基、甲砜基乙基、甲砜基丙基、乙砜基乙基、乙砜基丙基、2-羟基-2-甲基丙基、3-羟基-3-甲基丁基、氧杂环丁-3-基、四氢呋喃-3-基、四氢-2H-吡喃-4-基,或者R15、R16与其相连的氮原子构成取代或非取代的4-6元杂脂环基,选自以下基团:
R18选自-H、甲基、乙基、甲酰基、乙酰基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基,
R19和R20各自独立地选自-H、甲基、乙基、羟基、氰基、氟。
根据本发明的一个方面,提供一种式(I)所示化合物、其异构体、水合物、溶剂化物、其药学上可接受的盐及其前药,
式(I)中,
X为N或CH;
R2为-H、-F、-Cl、甲基或甲氧基;
R3选自-H、-F、-Cl、-Br、羟基、羧基、氰基、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、丙氧基、异丙氧基、环丙基氧基、环丁基氧基、甲硫基、乙硫基、丙硫基、异丙硫基、氟甲基、二氟甲基、三氟甲基、氟甲氧基、二氟甲氧基、三氟甲氧基、乙炔基、乙烯基、环丙基、环丁基、环丙基甲基、环丁基甲基、氨基、甲氨基、乙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基、或以下基团:
q为2-3的整数,
Rs选自-H、甲基、乙基,Rp选自-H、甲基、乙基,
R'、R”分别独立的选自-H、甲基、乙基、丙基、异丙基、环丙基、环丁基,
R7选自-H、-F、羟基、氰基、羧基、氨基、甲基、乙基、丙基、异丙基、甲氧基、乙氧基、丙氧基、异丙氧基、甲氨基、乙氨基、二甲氨基;
R4为-T1-R8,
p1为0-3的整数,p2为2-3的整数;
Rp选自-H、甲基、乙基;
R8选自-H、F、-Cl、羟基、氨基、氰基、氟甲氧基、二氟甲氧基、三氟甲氧基、甲基、乙基、丙基、丁基、己基、异丙基、氟甲基、二氟甲基、三氟甲基、环丙基、环丁基、环戊基、环己基、甲氧基、乙氧基、丙氧基、丁氧基、异丙氧基、甲硫基、乙硫基、丙硫基、异丙硫基、甲氨基、乙氨基、丙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基或以下基团:
R12为-H、-F、甲基、乙基,
R13为-H、-F、羟基、羟甲基、氰基、甲基、乙基、甲氧基、或–NR15R16,
Rs1、Rs2分别独立地选自-H、甲基;
R15、R16分别独立地为-H、甲基、乙基、丙基、异丙基、羟乙基、羟丙基、氰基甲基、氰基乙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、异丙氧基乙基、异丙氧基丙基、环丙基、环丁基、二甲氨基乙基、二甲氨基丙基、二乙氨基乙基、二乙氨基丙基、甲基乙基氨基乙基、甲基乙基氨基丙基、氟乙基、氟丙基、甲硫基乙基、甲硫基丙基、乙硫基乙基、乙硫基丙基、异丙硫基乙基、异丙硫基丙基、甲砜基乙基、甲砜基丙基、乙砜基乙基、乙砜基丙基、2-羟基-2-甲基丙基、3-羟基-3-甲基丁基、氧杂环丁基、四氢呋喃基、四氢吡喃基,或者R15、R16与其相连的氮原子构成取代或非取代的4-6元杂脂环基,选自以下基团:
R18选自-H、甲基、乙基、甲酰基、乙酰基、羟乙基、羟丙基、氟乙基、氟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基,
R19和R20各自独立地选自-H、甲基、乙基、羟基、氰基、氟、甲酰基、乙酰基、羟乙基、羟丙基、氟乙基、氟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基、氨基、甲氨基、二甲氨基、甲氧基、乙氧基,
在优选的方案中,L为-O-,且,当R4为4-乙基-哌嗪-1-基时,R2和R3不同时为氢。
在进一步优选的方案中,X为N;
L为-O-;
R2为-H、-F、-Cl、甲基或甲氧基;
R3选自-H、-F、-Cl、羟基、羧基、氰基、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、丙氧基、异丙氧基、环丙基氧基、环丁基氧基、甲硫基、乙硫基、丙硫基、异丙硫基、氟甲基、二氟甲基、三氟甲基、环丙基、环丁基、环丙基甲基、环丁基甲基、氨基、甲氨基、乙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基、甲氧基乙氧基、乙氧基乙氧基、氨基甲酰基(NH2CO-)、甲砜基;
R4为-T1-R8,
p1为0,p2为2-3的整数;
Rp选自-H、甲基、乙基;
R8选自甲氨基、乙氨基、丙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基或以下基团:
R12为-H、-F、甲基、乙基,
R13为-H、-NR15R16,
Rs1、Rs2分别独立地选自H、甲基;
R15、R16分别独立地为-H、甲基、乙基、丙基、异丙基、羟乙基、羟丙基、氰基甲基、氰基乙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、异丙氧基乙基、异丙氧基丙基、环丙基、环丁基、二甲氨基乙基、二甲氨基丙基、二乙氨基乙基、二乙氨基丙基、甲基乙基氨基乙基、甲基乙基氨基丙基、氟乙基、氟丙基、甲硫基乙基、甲硫基丙基、乙硫基乙基、乙硫基丙基、异丙硫基乙基、异丙硫基丙基、甲砜基乙基、甲砜基丙基、乙砜基乙基、乙砜基丙基、2-羟基-2-甲基丙基、3-羟基-3-甲基丁基、氧杂环丁-3-基、四氢呋喃-3-基、四氢-2H-吡喃-4-基,或者R15、R16与其相连的氮原子构成取代或非取代的4-6元杂脂环基,选自以下基团:
R18选自-H、甲基、乙基、甲酰基、乙酰基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基,
R19和R20各自独立地选自-H、甲基、乙基、羟基、氰基、氟、羟乙基、羟丙基、氟乙基、氟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基、氨基、甲氨基、二甲氨基、甲氧基、乙氧基;
在进一步优选的方案中,X为N;
L为-O-;
R2为-H、-F、-Cl、甲基或甲氧基;
R3选自-H、-F、-Cl、羟基、羧基、氰基、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、丙氧基、异丙氧基、环丙基氧基、环丁基氧基、甲硫基、乙硫基、丙硫基、异丙硫基、氟甲基、二氟甲基、三氟甲基、环丙基、环丁基、环丙基甲基、环丁基甲基、氨基、甲氨基、乙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基、甲氧基乙氧基、乙氧基乙氧基、氨基甲酰基(NH2CO-)、甲砜基;
R12为-H、-F、甲基、乙基,
R13为-H、-NR15R16,
Rs1、Rs2为H,
R15、R16分别独立地为-H、甲基、乙基、丙基、异丙基、羟乙基、羟丙基、氰基甲基、氰基乙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、异丙氧基乙基、异丙氧基丙基、环丙基、环丁基、二甲氨基乙基、二甲氨基丙基、二乙氨基乙基、二乙氨基丙基、甲基乙基氨基乙基、甲基乙基氨基丙基、氟乙基、氟丙基、甲硫基乙基、甲硫基丙基、乙硫基乙基、乙硫基丙基、异丙硫基乙基、异丙硫基丙基、甲砜基乙基、甲砜基丙基、乙砜基乙基、乙砜基丙基、2-羟基-2-甲基丙基、3-羟基-3-甲基丁基、氧杂环丁-3-基、四氢呋喃-3-基、四氢-2H-吡喃-4-基,或者R15、R16与其相连的氮原子构成取代或非取代的4-6元杂脂环基,选自以下基团:
R18选自-H、甲基、乙基、甲酰基、乙酰基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基,
R19和R20各自独立地选自-H、甲基、乙基、羟基、氰基、氟。
根据本申请的一些实施方案,所述化合物的药学上可接受的盐为选自所述化合物的盐酸盐、氢溴酸盐、氢碘酸盐、高氯酸盐、硫酸盐、硝酸盐、磷酸盐、甲酸盐、乙酸盐、丙酸盐、羟基乙酸盐、乳酸盐、琥珀酸盐、马来酸盐、酒石酸盐、苹果酸盐、柠檬酸盐、富马酸盐、葡萄糖酸盐、安息香酸盐、扁桃酸盐、甲磺酸盐、羟乙基磺酸盐、苯磺酸盐、草酸盐、棕榈酸盐、2-萘磺酸盐、对甲苯磺酸盐、环己氨基磺酸盐、水杨酸盐、己糖酸盐、三氟乙酸盐、铝盐、钙盐、氯普鲁卡因盐、胆碱盐、二乙醇胺盐、乙二胺盐、锂盐、镁盐、钾盐、钠盐和锌盐中的一种或多种。
本发明的另一方面涉及所述式(I)的化合物、其异构体、水合物、溶剂化物、药学上可接受的盐或前药在制备治疗与酪氨酸激酶FGFR4相关的疾病及自身免疫疾病的药物中的应用,其中,所述与酪氨酸激酶FGFR4相关的疾病及自身免疫疾病包括眼底疾病、干眼症、银屑病、白癜风、皮炎、斑秃、类风湿性关节炎、结肠炎、多重硬化、系统性红斑狼疮、克罗恩病、动脉粥样化、肺纤维化、肝纤维化、骨髓纤维化、非小细胞肺癌、小细胞肺癌、乳腺癌、胰腺癌、神经胶质瘤、胶质母细胞瘤、卵巢癌、子宫颈癌、结肠直肠癌、黑色素瘤、子宫内膜癌、前列腺癌、膀胱癌、白血病、胃癌、肝癌、胃肠间质瘤、甲状腺癌、慢性粒细胞白血病、急性髓细胞性白血病、非霍奇金淋巴瘤、鼻咽癌、食道癌、脑瘤、B细胞和T细胞淋巴瘤、淋巴瘤、多发性骨髓瘤、胆道癌肉瘤、胆管癌。
本发明的又一方面提供了一种药物组合物,该药物组合物包括本申请的式(I)所示的化合物、其异构体、水合物、溶剂化物、药学上可接受的盐或前药,以及一种或多种药学上可接受的载体或赋形剂。
根据本申请的一些实施方案,该药物组合物还可以包括一种或多种其他治疗剂。
本发明还涉及一种治疗酪氨酸激酶FGFR4介导的疾病或病症的方法,其包括对有需要的患者(人或其他哺乳动物,尤其是人)给药治疗有效量的式(I)化合物或其盐,所述酪氨酸激酶FGFR4介导的疾病或病症包括前述提及的那些。
发明详述
除非另有说明,在本申请(包括说明书和权利要求书)中使用的以下术语具有下面给出的定义。在本申请中,除非另外说明,使用“或”或“和”意味着“和/或”。此外,术语“包括”以及其它形式的使用,例如“包含”、“含有”和“具有”,不是限制性的。本文使用的章节标题仅仅是为了组织的目的,而不应解释为对所述的主题的限制。
除非有特殊说明,烷基表示具有指定数目碳原子的饱和直链、支链烃基,术语C1-C6烷基表示含有1至6个碳原子的烷基部分,同理C1-C3烷基表示含有1至3个碳原子的烷基部分,比如,C1-C6烷基包括甲基、乙基、丙基、异丙基、n-丁基、异丁基、仲-丁基、叔-丁基、n-戊基、3-(2-甲基)丁基、2-戊基、2-甲基丁基、新戊基、n-己基、2-己基和2-甲基戊基等。
当取代基术语例如“烷基”与其它取代基术语组合使用时,例如在术语“C1-C3烷氧基取代的C1-C3烷基”或“羟基取代C2-C6烷基”中,该连接取代基术语(例如烷基)旨在包含二价的部分,其中连接点通过所述连接取代基。“C1-C3烷氧基取代的C1-C3烷基”的实例包括但不限于甲氧基甲基、甲氧基乙基和乙氧基丙基等。“羟基取代C2-C6烷基”的实例包括但不限于羟基乙基、羟基丙基和羟基异丙基等。
烷氧基为由先前描述的直链或支链烷基与-O-形成的烷基-O-基团,例如,甲氧基、乙氧基等等。类似的,烷硫基由先前描述的直链或支链烷基与-S-形成的烷基-S-基团,例如,甲硫基,乙硫基等等。
烯基和炔基包括直链、支链烯基或炔基,术语C2-C3烯基或者C2-C3炔基表示具有至少一个烯基或炔基的直链或支链C2-C3烃基。
术语“卤代C1-C6烷基”表示在包括1到6个碳原子的烷基部分的一个或多个碳原子上具有一个或多个可以相同或不同的卤素原子的基团。“卤代C1-C6烷基”的实例可以包括但不限于-CF3(三氟甲基)、-CCl3(三氯甲基)、1,1-二氟乙基、2,2,2-三氟乙基和六氟异丙基等。类似的,术语“卤代C1-C6烷氧基”表示由所述的卤代C1-C6烷基与-O-形成的卤代烷基-O-基团,可以为例如三氟甲氧基、三氯甲氧基等等。
术语“C1-C3酰基”包括甲酰基(-CHO)、乙酰基(CH3CO-)、丙酰基(C2H5CO-)。
“环烷基”表示含有指定数目碳原子的非芳香的、饱和的、环状的烃基。例如,术语“(C3-C6)环烷基”指的是具有3-6个环碳原子的非芳香的环状烃环。示例性的“(C3-C6)环烷基”包括环丙基、环丁基、环戊基和环己基。
术语“芳基”表示包含芳香的单环或双环烃原子团的基团或部分,其含有6到12个碳环原子且具有至少一个芳香环。“芳基”的实例为苯基、萘基、茚基和二氢茚基(茚满基)。通常,在本发明化合物中,芳基优选为苯基。
在这里使用的术语“4-6元杂脂环基”,除非有特殊说明,代表未被取代的或已被取代的稳定的4至6元非芳香的单环饱和环体系,它们由碳原子以及从N,O,S中选的1至2个杂原子组成,其中N,S杂原子可以被随意氧化,N杂原子还可以被随意季铵化。这类杂环的例子包括但不限于氮杂环丁烷基、氧杂环丁烷基、硫杂环丁烷基、吡咯烷基、吡咯啉基、吡唑烷基、吡唑啉基、咪唑烷基、咪唑啉基、噁唑啉基、噻唑啉基、四氢呋喃基、二氢呋喃基、四氢噻吩基、1,3-二氧杂环戊烷基、哌啶基、哌嗪基、四氢吡喃基、二氢吡喃基、四氢噻喃基、1,3-二噁烷基、1,4-二噁烷基、1,3-氧硫杂环戊烷基、1,3-氧硫杂环己烷基、1,3-二噻烷基、1,4-氧硫杂环戊烷基、1,4-氧硫杂环己烷基、1,4-二噻烷基、吗啉基、硫吗啉基。
术语“羰基”指的是-C(O)-基。术语“卤素”和“卤”表示氯、氟、溴或碘取代基。“氧代”表示双键的氧部分;例如,直接连接到碳原子上形成一个羰基部分(C=O)。“羟基”旨在表示-OH原子团。本文所用术语“氰基”是指基团-CN。
术语“各自独立地”是指当一个以上的取代基选自许多可能的取代基时,那些取代基可以相同或不同。
很清楚,式I的化合物、异构体、晶型或前药及其可药用盐可以存在溶剂化形式和非溶剂化形式。例如溶剂化形式可以是水溶形式。本发明包括所有这些溶剂化的和未溶剂化的形式。
本申请中术语“异构体”为具有相同分子式的不同化合物,可以包括立体异构、互变异构等各种异构形式。“立体异构体”是仅原子在空间的排列方式不同的异构体。本文描述的某些化合物含有一个或多个不对称中心,且因此可以产生对映体、非对映体和其他依据绝对立体化学可以被定义为(R)-或(S)-的立体异构形式。本发明的化学实体、药物组合物和方法旨在包括所有这些可能的异构体,包括外消旋混合物、光学纯形式和中间的混合物。旋光(R)-和(S)-异构体可以使用手性合成子或手性试剂来制备,或使用常规技术来拆分。化合物的光学活性可以通过任何合适的方法进行分析,包括但不限于手性色谱法和旋光测定法,且可确定一种立体异构体超越其他异构体的优势程度。
可使用本领域技术人员已知的方法拆分本发明单独的异构体(或异构体富集的混合物)。例如,可如下进行所述拆分:(1)通过形成非对映异构体盐、复合物或其他衍生物;(2)通过与立体异构体特异性试剂的选择性反应,例如通过酶促氧化或还原;或(3)通过在手性环境中的气-液色谱或液相色谱,所述手性环境例如在手性载体上(例如结合有手性配体的硅胶)或在手性溶剂存在下。本领域技术人员将会理解,当将所需立体异构体通过上述分离方法之一转化成另一化学实体时,需要其他步骤来释放所需形式。或者,特异性立体异构体可通过使用光学活性试剂、底物、催化剂或溶剂的不对称合成法来合成,或通过不对称转化将一种对映异构体转化成另一种异构体。
当本文所述的化合物含有烯烃双键时,除非另有说明,其意指该化合物包括各种顺反异构体。
“互变异构体”是可通过互变异构化互相转换的结构上不同的异构体。“互变异构化”是异构化的一种形式,且包括质子移变或质子转移互变异构化,可认为它是酸碱化学的子集。“质子移变互变异构化”或“质子转移互变异构化”涉及伴有键级变换的质子迁移,往往是单键与相邻的双键的互换。当可能发生互变异构化时(例如,在溶液中),可达到互变异构体的化学平衡。互变异构化的一个实例为酮-烯醇互变异构化。
作为活性成分的本发明的化合物,以及制备该化合物的方法,都是本发明的内容。而且,一些化合物的晶型形式可以作为多晶体存在,这种形式也可以被包括在目前的发明里。另外,一些化合物可以和水(即水合物)或普通的有机溶剂一起形成溶剂化物,这种溶剂化物也被包括在此项发明的范畴内。
本发明的化合物可以以游离的形式用于治疗,或者在适当情况下以药学上可接受的盐或其它衍生物的形式用于治疗。如本文所用,术语“药学上可接受的盐”是指本发明的化合物的有机盐及无机盐,此盐适用于人类和低等动物,无过度毒性、刺激性、过敏反应等,具有合理的利益/风险比。胺,羧酸,膦酸盐,和其它类型的化合物的药学上可接受的盐在所属领域中是众所周知的。该盐可以由本发明的化合物与合适的游离碱或酸反应而成。包括但不限于,与无机酸如盐酸、氢溴酸、磷酸、硫酸、高氯酸或与有机酸如乙酸、草酸、马来酸、酒石酸、柠檬酸、琥珀酸、丙二酸形成的盐,或通过使用本领域熟知的方法,例如离子交换法,来得到这些盐。其他药学上可接受的盐包括己二酸盐、藻酸盐、抗坏血酸盐、天冬氨酸盐、苯磺酸盐、苯甲酸盐、硫酸氢盐、硼酸盐、丁酸盐、樟脑酸盐、樟脑磺酸盐、柠檬酸盐、二葡糖酸盐、十二烷基硫酸盐、乙磺酸盐、甲酸盐、富马酸盐、葡庚糖酸盐、甘油磷酸盐、葡萄糖酸盐、半硫酸盐、己酸盐、氢碘酸盐、2-羟基乙磺酸盐、乳糖酸盐、乳酸盐、月桂酸盐、月桂基硫酸盐、苹果酸盐、马来酸盐、甲烷磺酸盐、2-萘磺酸盐、烟酸盐、硝酸盐、油酸盐、棕榈酸盐、双羟萘酸盐、果胶酸盐、过硫酸盐、过3-苯基丙酸盐、磷酸盐、苦味酸盐、丙酸盐、硬脂酸盐、硫酸盐、硫氰酸盐、对甲苯磺酸盐、十一烷酸盐等。代表性的碱或碱土金属盐包括钠、锂、钾、钙、镁等。其他药学上可接受的盐包括适当的无毒的铵、季铵,和使用诸如卤离子、氢氧根、羧酸根、硫酸根、磷酸根、硝酸根,低级烷基磺酸盐和芳基磺酸盐形成的胺基阳离子。
另外,本文所用术语“前药”是指一个化合物在体内可以转化为本发明式(I)所示的化合物。此转化受前体药物在血液中水解或在血液或组织中经酶转化为母体化合物的影响。
本发明的药物组合物包含本文所述结构式(I)化合物或其药学上可接受的盐、激酶抑制剂(小分子,多肽,抗体等)、免疫抑制剂、抗癌药、抗病毒剂、抗炎剂、抗真菌剂、抗生素或抗血管过度增生化合物的另外的活性剂;以及任何药学上可接受的载体、佐剂或赋形剂。
本发明的化合物可以作为单独使用,也可以与一种或多种其它本发明的化合物或与一种或多种其它药剂联合使用。当联合给药时,治疗剂可以配制成同时给药或顺序地在不同的时间给药,或者所述治疗剂可以作为单一组合物给药。所谓“组合疗法”,指的是使用本发明的化合物与另一种药剂一起使用,给药方式为每种药剂同时共同给药或每种药剂顺序给药,无论哪种情况,目的都是要达到药物的最佳效果。共同给药包括同时递送剂型,以及每种化合物分别的单独剂型。因此,本发明的化合物的给药可以与已知的本领域的其他疗法同时使用,例如,在癌症治疗中使用放射治疗或细胞生长抑制剂、细胞毒性剂、其它抗癌剂等附加疗法来改善癌症状。本发明并不限于给药的顺序;本发明的化合物可以先前施用,同时施用,或在其他抗癌剂或细胞毒性剂之后施用。
为了制备这一发明的药学成分,作为其活性成分的分子式(I)的一种或多种化合物或盐类可紧密的与药学载体混合在一起,这是根据传统的制药配料技术而进行的,其中的载体可根据按不同的给药方式(例如,口服或肠外给药)设计好的制备形式而采用多种多样的形式。适当的药学上可接受的载体在技术上是众所周知的。对一些这类药学可接受的载体的描述可以在《药学赋形剂手册》里找到,该书由美国药学会和英国药学社联合出版。
本发明药物组合物可以有以下形式,比如说,适合口服给药,例如药片,胶囊,药丸,药粉,持续释放的形式,溶液或悬浮液;用于胃肠外注射如透明液,悬浮液,乳状液;或者用于局部用药如膏,霜;亦或作为栓剂用于直肠给药。药学成分也可以单位剂量的形式适合用于精确剂量的一次性给药。该药学成分将包括一种传统的药学载体或赋形剂以及根据目前的发明制成的作为活性成分的化合物,另外,也可以包括其他的医学或药学制剂,载体,辅助剂,等等。
治疗性化合物也可给于哺乳动物而非人类。给一个哺乳动物所用的药物剂量将取决于该动物的种类以及它的疾病状况或其所处的失调状态。治疗性化合物可以以胶囊,大丸药,药片药水的形式喂给动物。也可以通过注射或灌输的方式让治疗性化合物进入动物体内。我们根据符合兽医实践标准的传统的方式制备好这些药物形式。作为一种可选择的方式,药学合成药可以同动物饲料混合在一起喂给动物,因此,浓缩的饲料添加剂或预拌和料可以备以混合普通的动物饲料。
本发明的又一目的是在于提供一种用于治疗有需要的受试者中癌症的方法,其包括给受试者施用含本发明的化合物的组合物的治疗有效量的一种方法。
本发明的化合物对于FGFR4具有优于其他受体的选择性,特别是优于其他FGF受体,例如FGFR1、FGFR2和FGFR3。因此,本发明涉及作为选择性的FGFR4抑制剂的化合物。
考虑其作为FGFR4抑制剂的活性,以游离或可药用盐形式的式(I)化合物适用于治疗通过FGFR4蛋白质的活性介导的病状(诸如癌症)和/或对FGFR4的抑制具有反应性(特别是指以治疗上有益的方式)的病状,最特别的是如本文下文所提及的疾病或病症。
本发明的化合物可用于治疗癌症。具体而言,本发明的化合物可用于治疗选自肝癌、乳腺癌、神经胶母细胞瘤、前列腺癌、横纹肌肉瘤、胃癌、卵巢癌、肺癌、结肠癌的适应症。
本发明的化合物还可以用于治疗特征为阳性FGFR4表达的实体恶性肿瘤。
本发明的化合物还可以用于治疗特征为阳性KLB(β-klotho)表达的实体恶性肿瘤。
本发明的化合物还可以用于治疗特征为阳性FGF19表达的实体恶性肿瘤。
本发明的化合物还可以用于治疗特征为阳性FGFR4和阳性KLB表达的实体恶性肿瘤。
本发明的化合物还可以用于治疗特征为阳性FGFR4和阳性FGF19表达的实体恶性肿瘤。
本发明的化合物还可以用于治疗特征为阳性FGFR4、阳性KLB和阳性FGF19表达的实体恶性肿瘤。
如上文所述在FGFR4、KLB和/或FGF19中的任何阳性表达都可以通过技术人员已知的方法进行评价,例如RT-qPCR、Western免疫印迹法、ELISA、免疫组织化学。
因此,作为其它实施方案,本发明提供了式(I)化合物或其可药用盐在治疗中的用途。在其它实施方案中,该治疗是选自可以通过抑制FGFR4来治疗的疾病。在另一项实施方案中,该疾病是选自上文所提及的清单,合适地是肝癌。
在另一项实施方案中,本发明提供了治疗通过抑制FGFR4来治疗的疾病的方法,包括施用治疗上可接受量的式(I)化合物或其可药用盐。在其它实施方案中,该疾病是选自上文所提及的清单,合适地是肝癌。
因此,作为其它实施方案,本发明提供了式(I)化合物或其可药用盐在制备药物中的用途。在其它实施方案中,该药物是用于治疗可以通过抑制FGFR4来治疗的疾病。在另一项实施方案中,该疾病是选自上文所提及的清单,合适地是肝癌。
本发明还提供了制备相应化合物的方法,可以使用多种合成方法制备本文所述的化合物,包括下述实施例中所涉及的方法,本发明的化合物或者其药学上可接受的盐,异构体或水合物可以使用下述方法与有机化学合成领域已知的合成方法,或通过本领域技术人员理解对这些方法的变化方法合成,优选方法包括但不限于下述方法。
本发明终产物可通过以下方案制备,其中R1,R2,R3,R4,X,L如前文所定义,
中间体A中Q可以为卤素(优选为氯)或甲基砜基(亚砜基),当采用M为BocNH-的B类中间体时,步骤1的反应可在酸催化、中性条件或碱性条件下加热进行取代反应合成化合物(I’)。当中间体A中Q为氯时,也可通过Buchwald偶联反应合成化合物(I’);之后在酸性条件下脱去叔丁基氧羰基保护基,并进一步与丙烯酰氯合成终产物(I)。
本发明化合物的制备方法包含上面各中间体的制备,
其中中间体(B)制备方法如下,
第1步:化合物(B2)与(Boc)2O反应得到化合物(B3),X’可以为Cl、F、Br或I;
第2步:化合物(B3)与R4-H(胺或者醇)在碱性或中性条件下进行反应得到化合物(B4)。当X’为Cl、Br或I时,也可通过Buchwald偶联反应得到化合物(B4);
第3步:化合物(B4)与还原剂反应生成中间体(B)。
第2步所述的碱选自碳酸铯,三乙胺,氢化钠,双(三甲基硅基)氨基钠等无机碱或者有机碱中一种或两种以上的组合,Buchwald条件优选Pd2(dba)3,XantPhos和碳酸铯的组合;
第3步所述的还原剂选自氯化亚锡,氢气与钯碳组合,氢气与雷尼镍组合,锌粉与酸组合,铁粉与酸组合等还原剂体系;
中间体(A)的一种制备方法如下,
第1步:化合物(A2)在碱存在的条件下与A1进行取代反应得到(A3);
第2步:化合物(A3)在脱水剂的条件下酰胺脱水成为化合物(A)。
本发明提供了上述反应的优先实施方案,优选地,
第1步,所述的碱选自有机或无机碱,例如三乙胺,N’N-二异丙基乙基胺,氢化钠,双(三甲基硅基)氨基钠,正丁基锂中一种或两种以上的组合;
优选地,所述脱水剂选自三氯氧磷,三氯化铝,五氧化二磷,氯化磷(五氯化磷或三氯化磷)等。
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合具体实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅用以解释本发明,并不用于限定本发明。实施例中未注明具体技术或条件的,按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。本文所使用的术语“和/或”包括一个或多个相关的所列项目的任意的和所有的组合。本申请中部分化合物的命名通过chemdraw产生后翻译为中文。
具体实施方式
一.化学试剂来源
反应溶剂由中国国药试剂提供
普通反应化学原料由伊诺凯、安耐吉、麦克林、百灵威、药石等公司提供
薄层层析硅胶板(厚度0.5mm,1mm,200X200 mm)由烟台新诺化工有限公司提供
硅胶(200-300目)由中国国药试剂公司提供
二.化学简称
DMF:N’N-二甲基甲酰胺
DIEA:N’N-二异丙基乙基胺
NMP:N-甲基吡咯烷酮
Pd(OAc)2:醋酸钯
Pd2(dba)3:三(二亚苄基茚丙酮)二钯
Xantphos:4,5-双二苯基膦-9,9-二甲基氧杂蒽
Binap:1,1'-联萘-2,2'-双二苯膦
(Boc)2O:二碳酸二叔丁酯
三.中间体的制备
A系列中间体
中间体A1.2-氯-4-((2-异丙氧基苯基)氨基)嘧啶-5-甲腈
步骤1).2-氯-4-((2-异丙氧基苯基)氨基)嘧啶-5-甲酰胺的合成
分别将2,4-二氯嘧啶-5-甲酰胺(1.9g,10mmol),2-异丙氧基苯胺(1.65g,11mmol)和三乙胺(2g,20mmol)加入DMF(10mL),室温搅拌反应2小时,加水打浆,过滤,干燥得白色固体产物2.5g,收率82%,MS:307[M+H]+;
步骤2).2-氯-4-((2-异丙氧基苯基)氨基)嘧啶-5-甲腈的合成
将2-氯-4-((2-异丙氧基苯基)氨基)嘧啶-5-甲酰胺(307mg,1mmol)加入到三氯氧磷(2mL)中,加热至120摄氏度,搅拌反应5小时,浓缩,用饱和碳酸氢钠溶液洗涤得微黄色固体产物220mg,收率76%,MS:289[M+H]+。
同中间体A1的反应步骤,由带有不同取代基的苯胺类化合物代替以上步骤1中的2-异丙氧基苯胺进行反应得到如下中间体A2-A23。以下表1示出了中间体A2-A23的结构、名称和质谱数据。
表1中间体A2-A23的结构、名称和质谱数据
B系列中间体
中间体B1.(2-氨基-5-(4-乙基哌嗪-1-基)苯基)氨基甲酸叔丁酯的制备
步骤1)N,N-二叔丁氧羰基-2-硝基-5-氟苯胺的制备
分别将5-氟-2-硝基苯胺(1.6g,10mmol),(Boc)2O(4.7g,22mmol)和DMAP(0.37g,3mmol)加入二氯甲烷溶液中,室温搅拌过夜,浓缩,柱层析(硅胶,流动相为石油醚/乙酸乙酯=10/1)纯化得到亮黄色固体产物3.3g,MS:357[M+H]+;
步骤2)(5-(4-乙基哌嗪-1-基)-2-硝基苯基)氨基甲酸叔丁酯的制备
N,N-二叔丁氧羰基-2-硝基-5-氟苯胺(3.3g,9.2mmol)和乙基哌嗪(3mL)分别加入到DMF中,加热至120℃反应8小时,冷却,浓缩,柱层析纯化得到黄色固体3.1g,MS:351[M+H]+;
步骤3)(2-氨基-5-(4-乙基哌嗪-1-基)苯基)氨基甲酸叔丁酯的制备
(5-(4-乙基哌嗪-1-基)-2-硝基苯基)氨基甲酸叔丁酯(3.1g,8.9mmol)加入Pd/C的甲醇溶液中,氢气置换2次,室温搅拌反应3小时,过滤,浓缩,由二氯甲烷打浆,过滤得白色固体2.5g,MS:321[M+H]+。
采用与中间体B1的合成类似的反应步骤,由带有不同取代基的5-氟2-硝基苯胺类化合物代替以上步骤1中的5-氟2-硝基苯胺、和由不同的碱取代步骤2中的乙基哌嗪进行反应得到如下中间体B2-B56。以下表2示出了中间体B2-B56的结构、名称和质谱数据。
表2.中间体B2-B56的结构、名称和质谱数据
四.具体实施例的制备
实施例1:N-(2-((5-氰基-4-((2-异丙氧基苯基)氨基)嘧啶-2-基)氨基)-5-(4-甲基哌嗪-1-基)苯基)丙烯酰胺
步骤1:(2-((5-氰基-4-((2-异丙氧基苯基)氨基)嘧啶-2-基)氨基)-5-(4-甲基哌嗪-1-基)苯基)氨基甲酸叔丁酯的合成
将中间体2-氯-4-((2-异丙氧基苯基)氨基)嘧啶-5-甲腈(160mg,0.55mmol),(2-氨基-5-(4-甲基哌嗪-1-基)苯基)氨基甲酸叔丁酯(155mg,0.5mmol)和三氟乙酸(催化量,20微升),加入仲丁醇中加热反应12小时,冷却,浓缩,使用饱和碳酸钠溶液洗涤,有机相浓缩并使用硅胶柱层析得到白色固体产物240mg,收率86%,MS:559[M+H]+;
步骤2:N-(2-((5-氰基-4-((2-异丙氧基苯基)氨基)嘧啶-2-基)氨基)-5-(4-甲基哌嗪-1-基)苯基)丙烯酰胺的合成
(2-((5-氰基-4-((2-异丙氧基苯基)氨基)嘧啶-2-基)氨基)-5-(4-甲基哌嗪-1-基)苯基)氨基甲酸叔丁酯(120mg,0.2mmol)加入到三氟乙酸(1mL)和二氯甲烷(2mL)的溶剂中,室温搅拌反应3小时,浓缩得灰色油状物溶于干燥四氢呋喃(1mL)中,在冰水浴条件下缓慢滴加丙烯酰氯(28mg,0.3mmol),并继续搅拌反应0.5小时,加水淬灭,饱和碳酸氢钠溶液洗涤,二氯甲烷萃取,有机相干燥,浓缩,由制备硅胶薄板(流动相甲醇/二氯甲烷体积比8/100)纯化得白色固体产物45mg。1H NMR(400MHz,DMSO-d6)δ9.66(s,1H),8.97(s,1H),8.47(s,1H),8.24(s,1H),7.94(s,1H),7.33(d,J=25.8Hz,2H),7.08(s,2H),6.82(d,J=9.1Hz,1H),6.72(s,1H),6.50(dd,J=16.9,10.2Hz,1H),6.24(dd,J=17.0,2.0Hz,1H),5.78–5.70(m,1H),4.74–4.47(m,1H),3.14(s,4H),2.47(d,J=5.2Hz,4H),2.24(s,3H),1.33–1.21(m,6H).MS:513[M+H]+。
下表中化合物参照实施例1的制备方法,采用相应的中间体反应制备得到,下表3列出了实施例2-81制备的化合物的结构、名称及其核磁氢谱和质谱表征数据。
表3.实施例2-81制备的化合物的结构、名称及其核磁氢谱和质谱表征数据
实施例82:N-(2-((5-氰基-4-((2-异丙氧基苯基)氨基)吡啶-2-基)氨基)-5-(4-(二甲基氨基)哌啶-1-基)苯基)丙烯酰胺
步骤1)6-氯-4-((2-异丙氧基苯基)氨基)烟酰胺的制备
在冰盐浴条件下向2-异丙氧基苯胺(300mg,2mmol)的四氢呋喃(5mL)溶液中缓慢滴加HMDSNa(2N,1mL),继续搅拌反应半小时,随后滴加入2,4-二氯-5-烟酰胺(190mg,1mmol)的四氢呋喃(1mL)溶液,在冰水浴条件下搅拌反应过夜,加水淬灭打浆,过滤得浅黄色固体230mg,收率75%,MS:306[M+H]+。
步骤2)6-氯-4-((2-异丙氧基苯基)氨基)烟腈的制备
6-氯-4-((2-异丙氧基苯基)氨基)烟酰胺(220mg,0.8mmol)的三氯氧磷(2mL)溶液加热至回流反应3小时,冷却,浓缩,饱和碳酸氢钠洗涤,二氯甲烷萃取,取有机相干燥,浓缩得黄色固体160mg,MS:288[M+H]+。
步骤3)(2-((5-氰基-4-((2-异丙氧基苯基)氨基)吡啶-2-基)氨基)-5-(4-(二甲基氨基)哌啶-1-基)苯基)氨基甲酸叔丁酯的制备
将6-氯-4-((2-异丙氧基苯基)氨基)烟腈(120mg,0.4mmol),(2-氨基-5-(4-(二甲基氨基)哌啶-1-基)苯基)氨基甲酸叔丁酯(135mg,0.4mmol),Pd2(dba)3(10mg),Xantphos(10mg)以及碳酸钠(110mg,1mmol)分别溶于装有二氧六环(5mL)和水(0.5mL)的封管中,反应体系由氩气置换后在120℃加热反应10小时,冷却,过滤,滤液浓缩后直接由制备薄层板(1mm,硅胶)纯化得到浅黄色固体产物104mg,MS:586[M+H]+。
步骤4):(2-((5-氰基-4-((2-异丙氧基苯基)氨基)吡啶-2-基)氨基)-5-(4-(二甲基氨基)哌啶-1-基)苯基)氨基甲酸叔丁酯(88mg,0.15mmol)加入含有三氟乙酸(1mL)的二氯甲烷(3mL)溶液中,室温搅拌1小时,浓缩,加入无水四氢呋喃(2mL),随后在冰水浴条件下滴加丙烯酰氯(40微升)并继续搅拌半小时,加水淬灭,二氯甲烷萃取,饱和碳酸氢钠洗涤,有机相干燥,浓缩并经制备型薄板(0.5mm,负载硅胶)纯化(展开体系V二氯甲烷/甲醇=11/1)得到白色固体产物33mg。1H NMR(400MHz,DMSO-d6)δ9.53(s,1H),8.23(s,1H),8.18(s,1H),7.80(s,1H),7.30(d,J=2.7Hz,1H),7.26–7.05(m,4H),6.93(td,J=7.5,1.5Hz,1H),6.74(dd,J=8.9,2.8Hz,1H),6.45(dd,J=17.0,10.1Hz,1H),6.20(dd,J=17.0,2.0Hz,1H),5.85(s,1H),5.72(dd,J=10.1,2.0Hz,1H),4.56(p,J=6.1Hz,1H),3.66(d,J=12.4Hz,2H),2.71–2.60(m,2H),2.53(s,1H),2.37(s,6H),1.89(d,J=11.1Hz,2H),1.54(dd,J=13.8,10.0Hz,2H),1.20(d,J=6.0Hz,6H).MS:540[M+H]+。
实施例83:N-(2-((5-氰基-4-((2-异丙氧基苯基)氨基)吡啶-2-基)氨基)-5-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)丙烯酰胺
同实施例82操作,由(2-氨基-5-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基甲酸叔丁酯代替步骤实施例82步骤3)的(2-氨基-5-(4-(二甲基氨基)哌啶-1-基)苯基)氨基甲酸叔丁酯进行反应得到目标产物;1H NMR(400MHz,DMSO-d6)δ9.53(s,1H),8.21(s,1H),8.16(s,1H),7.80(s,1H),7.29(d,J=2.8Hz,1H),7.25–7.05(m,4H),6.93(td,J=7.5,1.5Hz,1H),6.72(dd,J=8.9,2.8Hz,1H),6.45(dd,J=16.9,10.2Hz,1H),6.20(dd,J=17.0,2.1Hz,1H),5.83(s,1H),5.72(dd,J=10.1,2.0Hz,1H),4.61–4.50(m,1H),3.63(d,J=12.3Hz,2H),3.35(br,4H),2.65(td,J=12.2,2.2Hz,2H),2.55-2.50(m,1H),2.41–2.21(m,4H),2.16(s,3H),1.83(d,J=12.3Hz,2H),1.47(dd,J=11.7,3.6Hz,2H),1.20(d,J=6.1Hz,6H).MS:595[M+H]+。
实施例84:N-(2-((5-氰基-4-((2-异丙氧基苯基)氨基)吡啶-2-基)氨基)-5-(4-乙基哌嗪-1-基)苯基)丙烯酰胺
同实施例82操作,由(2-氨基-5-(4-乙基哌嗪-1-基)苯基)氨基甲酸叔丁酯代替步骤实施例82步骤3)的(2-氨基-5-(4-(二甲基氨基)哌啶-1-基)苯基)氨基甲酸叔丁酯进行反应得到目标产物;1H NMR(400MHz,DMSO-d6)δ9.55(s,1H),8.22-8.14(m,2H),7.80(s,1H),7.31–7.05(m,5H),6.93(td,J=7.5,1.5Hz,1H),6.74(dd,J=8.9,2.8Hz,1H),6.45(dd,J=17.0,10.1Hz,1H),6.20(dd,J=17.0,2.0Hz,1H),5.85(s,1H),5.72(dd,J=10.1,2.0Hz,1H),4.56(p,J=6.0Hz,1H),3.08(t,J=5.0Hz,4H),2.50(br,4H),2.38(q,J=7.2Hz,2H),1.20(d,J=6.0Hz,6H),1.04(t,J=7.2Hz,3H).MS:526[M+H]+。
实验例1.
小分子化合物抑制FGFR4激酶活性和FGFR4 V550L突变激酶活性的测试,测试方法如下:
1)化合物的稀释:
在96孔板a中,将化合物用DMSO溶液按3倍比例稀释,形成11个梯度,第12个梯度为纯DMSO溶液(作为阳性对照);取一块新的96孔板b,将上述溶液用超纯水稀释25倍(DMSO浓度为4%)
2)将化合物转盘到384孔板:
将上述96孔板b中用超纯水稀释过的化合物溶液转盘到384孔板相应的孔中。
3)加4×激酶溶液:用排枪取2.5μl上述4×激酶溶液加入到384孔板相应的反应孔中,混匀室温预反应5分钟。
4)加2×底物/ATP混合液:用排枪取5μl上述2×底物/ATP混合液到384孔板相应的反应孔中。
5)阴性对照:在384孔板中设置阴性对照孔,每孔加入2.5μl 4×底物、2.5μl 4×酶溶液、2.5μl 1×Kinase Assay Buffer和2.5μl含4%DMSO的超纯水。
6)离心混匀,避光室温反应2小时。
7)终止酶促反应:
吸取5μl上述4×终止液到384孔板相应孔,离心混匀,室温反应5分钟。
8)显色反应:
吸取5μl上述4×检测液加入到384孔板相应孔,离心混匀,室温反应1小时。
9)将384孔板放入读板仪,调取相应的程序检测信号。
10)IC50分析:
孔读值=10000*EU665值/EU615值
抑制率=(阳性对照孔读值-实验孔读值)/(阳性对照孔读值-阴性对照孔读值)*100%
将药物浓度和相应抑制率输入GraphPad Prism 5处理可计算出相应的IC50。
FGFR4激酶活性抑制分子筛选实验条件:
反应体系中FGFR4激酶终浓度3.85nM,ATP的终浓度为100μM,底物ULightTM-labeled JAK-1(Tyr1023)Peptide的终浓度100nM,酶促反应时间为2小时。
反应体系中化合物最高终浓度为2.5μM,经3倍梯度稀释后共11个浓度,最低终浓度为0.042nM。DMSO终浓度为1%。
FGFR4 V550L激酶活性抑制分子筛选实验条件:
反应体系中FGFR4 V550L激酶终浓度1nM,ATP的终浓度为10μM,底物ULightTM-labeled PolyGT的终浓度100nM,酶促反应时间为2小时。
反应体系中化合物最高终浓度为2.5μM,经3倍梯度稀释后共11个浓度,最低终浓度为0.042nM。DMSO终浓度为1%。
表4列出了本专利中部分化合物对酪氨酸激酶FGFR4和对V550L突变的酪氨酸激酶FGFR4抑制活性的测定结果,其中A表示IC50小于或等于10nM,B表示IC50大于10nM但小于或等于50nM,C表示IC50大于50nM但小于或等于100nM,D表示IC50大于100nM,且D小于或等于1000nM,NT表示未有相关值。
表4:本发明化合物对FGFR4激酶和V550L突变的酪氨酸激酶FGFR4抑制活性测定结果
实验例2.
化合物抑制细胞增殖的测试,具体方法如下:
1.取培养至对数生长期的细胞,吹打均匀,转移至15mL离心管中,按照1000rpm的条件室温离心4分钟;
2.弃去上清液,加入5mL完全培养液,吹打均匀,取10μL细胞悬浮液和10μL 0.4%胎盼蓝混匀,在细胞计数仪下进行计数并确保活细胞比例在90%以上;
3.按照表5所示条件每孔接种80μL的细胞混悬液到96孔板中,96孔板外周36孔不加细胞仅加无菌水,仅里面60孔用于细胞实验和对照;
4.5×化合物稀释:将化合物以4倍比例进行浓度梯度稀释,共9个浓度,用完全培养基完成80倍整体稀释,该浓度为最终药物浓度的5倍,DMSO浓度为1.25%;
5.在96孔板中实验孔每孔加入20μL对应的不同浓度梯度的化合物,阳性和阴性对照孔加入20μL完全培养液摇匀,每孔中DMSO的终浓度为0.25%;
6.培养72h后每孔加入10μL CCK-8试剂,37℃培养1-2h;于450nm处读其OD值;
7.细胞存活率(%)=[(As-Ab)/(Ac-Ab)]*100%
As:实验孔(含有细胞的培养基、CCK-8、化合物)
Ac:对照孔(含有细胞的培养基、CCK-8)
Ab:空白孔(不含细胞和化合物的培养基、CCK-8)
8.将数值导入Graphpad Prism5软件进行IC50计算。
表5.细胞基本信息和接种条件
表6列出了本申请中部分化合物对Ba/F3 ETV6-FGFR4细胞和Ba/F3 ETV6-FGFR4-V550L细胞增殖抑制活性的测定结果,其中A表示IC50小于或等于10nM,B表示IC50大于10nM但小于或等于50nM,C表示IC50大于50nM但小于或等于100nM,D表示IC50大于100nM,且D小于或等于1000nM,NT表示未有相关值。
表6:本发明化合物对Ba/F3 ETV6-FGFR4细胞和Ba/F3 ETV6-FGFR4-V550L细胞增殖抑制活性测定结果
本发明所提供的生物学数据表明,本发明的化合物有利于治疗或预防由于FGFR4激酶异常而引起的疾病,包括FGFR4基因突变(V550L,V550M等)引起的疾病,包括原发性和转移性癌症,包括实体瘤。此类癌症包括但不限于:非小细胞肺癌、小细胞肺癌、乳腺癌、胰腺癌、神经胶质瘤、胶质母细胞瘤、卵巢癌、子宫颈癌、结肠直肠癌、黑色素瘤、子宫内膜癌、前列腺癌、膀胱癌、白血病、胃癌、肝癌、胃肠间质瘤、甲状腺癌、慢性粒细胞白血病、急性髓细胞性白血病、非霍奇金淋巴瘤、鼻咽癌、食道癌、脑瘤、B细胞和T细胞淋巴瘤、淋巴瘤、多发性骨髓瘤、胆道癌肉瘤、胆管癌。本发明的化合物也包括治疗耐一种或多种其它治疗方法的癌症。本发明的化合物还可用于与FGFR4激酶有关的除了癌症以外的其他疾病,包括但不限于眼底疾病,银屑病、风湿性关节炎、动脉粥样化、肺纤维化、肝纤维化。本发明的化合物可以作为单一疗法或联合疗法,可以与多个本发明的化合物联合用药或与本发明以外的其他药物联合用药。
以上所述是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明所述原则的前提下,本发明的实施方式还可以作出若干改进和修饰,这些改进和修饰也应视为本发明的保护范围。
Claims (14)
1.一种式(I)所示化合物、及其药学上可接受的盐,
式(I)中,
X为N或CH;
R2为氢、卤素、C1-C3烷氧基、C1-C3烷基;
R3选自氢、卤素、羟基、氰基、羧基、C1-C6烷基、卤代C1-C6烷基、C3-C6环烷基、C1-C3烷氧基、或以下基团:
q为1-3的整数,
Rs选自-H、C1-C3烷基,
R'、R”分别独立地为-H、C1-C3烷基、C3-C4环烷基,
R7选自C1-C3烷氧基;
R4为-T1-R8,
p1为0-3的整数,p2为2-3的整数;
Rp选自-H、甲基、乙基;
R8选自-H、F、-Cl、羟基、氨基、氰基、氟甲氧基、二氟甲氧基、三氟甲氧基、甲基、乙基、丙基、丁基、己基、异丙基、氟甲基、二氟甲基、三氟甲基、环丙基、环丁基、环戊基、环己基、甲氧基、乙氧基、丙氧基、丁氧基、异丙氧基、甲硫基、乙硫基、丙硫基、异丙硫基、甲氨基、乙氨基、丙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基或以下基团:
R12为-H、-F、甲基、乙基,
R13为–NR15R16,
Rs1、Rs2分别独立地选自H、甲基;
R15、R16分别独立地为甲基、乙基、丙基、异丙基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、异丙氧基乙基、异丙氧基丙基、环丙基、环丁基、二甲氨基乙基、二甲氨基丙基、二乙氨基乙基、二乙氨基丙基、甲基乙基氨基乙基、甲基乙基氨基丙基、氟乙基、氟丙基、甲硫基乙基、甲硫基丙基、乙硫基乙基、乙硫基丙基、异丙硫基乙基、异丙硫基丙基、甲砜基乙基、甲砜基丙基、乙砜基乙基、乙砜基丙基、2-羟基-2-甲基丙基、3-羟基-3-甲基丁基、氧杂环丁基、四氢呋喃基、四氢吡喃基,或者R15、R16与其相连的氮原子构成取代或非取代的4-6元杂脂环基,选自以下基团:
R18选自甲基、乙基、甲酰基、乙酰基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基,
R19和R20各自独立地选自-H、甲基、乙基、羟基、氰基、氟;
2.根据权利要求1所述的式(I)的化合物及其药学上可接受的盐,其中,R2为-H、-F、-Cl、甲基或甲氧基。
4.根据权利要求1所述的式(I)的化合物及其药学上可接受的盐,其中,R4为-T1-R8,
p1为0,p2为2-3的整数;
Rp选自-H、甲基、乙基;
R8选自甲氨基、乙氨基、丙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基或以下基团:
R12为-H、-F、甲基、乙基,
R13为-NR15R16,
Rs1、Rs2分别独立地选自H、甲基;
R15、R16分别独立地为甲基、乙基、丙基、异丙基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、异丙氧基乙基、异丙氧基丙基、环丙基、环丁基、二甲氨基乙基、二甲氨基丙基、二乙氨基乙基、二乙氨基丙基、甲基乙基氨基乙基、甲基乙基氨基丙基、氟乙基、氟丙基、甲硫基乙基、甲硫基丙基、乙硫基乙基、乙硫基丙基、异丙硫基乙基、异丙硫基丙基、甲砜基乙基、甲砜基丙基、乙砜基乙基、乙砜基丙基、2-羟基-2-甲基丙基、3-羟基-3-甲基丁基、氧杂环丁-3-基、四氢呋喃-3-基、四氢-2H-吡喃-4-基,或者R15、R16与其相连的氮原子构成取代或非取代的4-6元杂脂环基,选自以下基团:
R18选自甲基、乙基、甲酰基、乙酰基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基,
R19和R20各自独立地选自-H、甲基、乙基、羟基、氰基、氟。
5.根据权利要求1所述的式(I)的化合物及其药学上可接受的盐,其中,
R12为-H、-F、甲基、乙基,
R13为-NR15R16,
Rs1、Rs2为H,
R15、R16分别独立地为甲基、乙基、丙基、异丙基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、异丙氧基乙基、异丙氧基丙基、环丙基、环丁基、二甲氨基乙基、二甲氨基丙基、二乙氨基乙基、二乙氨基丙基、甲基乙基氨基乙基、甲基乙基氨基丙基、氟乙基、氟丙基、甲硫基乙基、甲硫基丙基、乙硫基乙基、乙硫基丙基、异丙硫基乙基、异丙硫基丙基、甲砜基乙基、甲砜基丙基、乙砜基乙基、乙砜基丙基、2-羟基-2-甲基丙基、3-羟基-3-甲基丁基、氧杂环丁-3-基、四氢呋喃-3-基、四氢-2H-吡喃-4-基,或者R15、R16与其相连的氮原子构成取代或非取代的4-6元杂脂环基,选自以下基团:
R18选自甲基、乙基、甲酰基、乙酰基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基,
R19和R20各自独立地选自-H、甲基、乙基、羟基、氰基、氟。
6.根据权利要求1所述的式(I)的化合物及其药学上可接受的盐,其中,X为N或CH;
R2为-H、-F、-Cl、甲基或甲氧基;
R3选自-H、-F、-Cl、-Br、羟基、羧基、氰基、甲基、乙基、丙基、异丙基、叔丁基、甲氧基、乙氧基、丙氧基、异丙氧基、氟甲基、二氟甲基、三氟甲基、环丙基、环丁基、环丙基甲基或以下基团:
q为2-3的整数,
Rs选自-H、甲基、乙基,
R'、R”分别独立的选自-H、甲基、乙基、丙基、异丙基、环丙基、环丁基,
R7选自甲氧基、乙氧基、丙氧基、异丙氧基;
R4为-T1-R8,
p1为0-3的整数,p2为2-3的整数;
Rp选自-H、甲基、乙基;
R8选自-H、F、-Cl、羟基、氨基、氰基、氟甲氧基、二氟甲氧基、三氟甲氧基、甲基、乙基、丙基、丁基、己基、异丙基、氟甲基、二氟甲基、三氟甲基、环丙基、环丁基、环戊基、环己基、甲氧基、乙氧基、丙氧基、丁氧基、异丙氧基、甲硫基、乙硫基、丙硫基、异丙硫基、甲氨基、乙氨基、丙氨基、二甲氨基、二乙氨基、N-甲基-N-乙基氨基或以下基团:
R12为-H、-F、甲基、乙基,
R13为-NR15R16,
Rs1、Rs2分别独立地选自-H、甲基;
R15、R16分别独立地为甲基、乙基、丙基、异丙基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、异丙氧基乙基、异丙氧基丙基、环丙基、环丁基、二甲氨基乙基、二甲氨基丙基、二乙氨基乙基、二乙氨基丙基、甲基乙基氨基乙基、甲基乙基氨基丙基、氟乙基、氟丙基、甲硫基乙基、甲硫基丙基、乙硫基乙基、乙硫基丙基、异丙硫基乙基、异丙硫基丙基、甲砜基乙基、甲砜基丙基、乙砜基乙基、乙砜基丙基、2-羟基-2-甲基丙基、3-羟基-3-甲基丁基、氧杂环丁基、四氢呋喃基、四氢吡喃基,或者R15、R16与其相连的氮原子构成取代或非取代的4-6元杂脂环基,选自以下基团:
R18选自甲基、乙基、甲酰基、乙酰基、羟乙基、羟丙基、甲氧基乙基、甲氧基丙基、乙氧基乙基、乙氧基丙基、甲砜基、乙砜基,
R19和R20各自独立地选自-H、甲基、乙基、羟基、氰基、氟,
7.根据权利要求6所述的式(I)的化合物及其药学上可接受的盐,其中,L为-O-,且,当R4为4-乙基-哌嗪-1-基时,R2和R3不同时为氢。
9.一种药用组合物,包括权利要求1-8中任一项所述的化合物或其药学上可接受的盐,与药学上可接受的载体或赋形剂。
10.如权利要求9所述的药用组合物,其中,所述药用组合物还包含一种或多种其它治疗剂。
11.根据权利要求1-8中任一项所述的化合物或其药学上可接受的盐在制备治疗与酪氨酸激酶FGFR4相关的疾病及自身免疫疾病的药物中的应用。
12.根据权利要求11所述的应用,其中所述与酪氨酸激酶FGFR4相关的疾病及自身免疫疾病包括眼底疾病、干眼症、银屑病、白癜风、皮炎、斑秃、类风湿性关节炎、结肠炎、多重硬化、系统性红斑狼疮、克罗恩病、动脉粥样化、肺纤维化、肝纤维化、骨髓纤维化、非小细胞肺癌、小细胞肺癌、乳腺癌、胰腺癌、神经胶质瘤、胶质母细胞瘤、卵巢癌、子宫颈癌、结肠直肠癌、黑色素瘤、子宫内膜癌、前列腺癌、膀胱癌、白血病、胃癌、肝癌、胃肠间质瘤、甲状腺癌、鼻咽癌、食道癌、脑瘤、淋巴瘤、多发性骨髓瘤、胆道癌肉瘤、胆管癌。
13.根据权利要求12所述的应用,其中,所述白血病包括慢性粒细胞白血病或急性髓细胞性白血病。
14.根据权利要求12所述的应用,其中,所述淋巴瘤包括非霍奇金淋巴瘤、B细胞或T细胞淋巴瘤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911337644 | 2019-12-23 | ||
CN2019113376449 | 2019-12-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113087671A CN113087671A (zh) | 2021-07-09 |
CN113087671B true CN113087671B (zh) | 2022-10-21 |
Family
ID=76575631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011516692.7A Active CN113087671B (zh) | 2019-12-23 | 2020-12-21 | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230125046A1 (zh) |
EP (1) | EP4083021A4 (zh) |
KR (1) | KR20220114643A (zh) |
CN (1) | CN113087671B (zh) |
AU (1) | AU2020414132B2 (zh) |
CA (1) | CA3162851A1 (zh) |
TW (1) | TWI781497B (zh) |
WO (1) | WO2021129561A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114560815A (zh) * | 2022-03-04 | 2022-05-31 | 北京工业大学 | (2-((5-氯-取代苯基氨基嘧啶-2-基)氨基)苯基)氨基甲酸叔丁酯类衍生物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2872491B1 (en) * | 2012-07-11 | 2021-05-05 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
DK3057943T3 (en) | 2013-10-18 | 2018-07-30 | Eisai R&D Man Co Ltd | PYRIMIDINE-FGFR4 INHIBITORS |
WO2016164703A1 (en) * | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
WO2016187028A1 (en) * | 2015-05-15 | 2016-11-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds, synthesis thereof, and intermediates thereto |
CN106187915A (zh) * | 2015-05-27 | 2016-12-07 | 上海翰森生物医药科技有限公司 | 具有alk与egfr双重活性的抑制剂及其制备方法和应用 |
CN106928150B (zh) * | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技(上海)有限公司 | 丙烯酰胺苯胺衍生物及其药学上的应用 |
WO2018072707A1 (zh) * | 2016-10-18 | 2018-04-26 | 保诺科技(北京)有限公司 | 芳香族醚类衍生物、其制备方法及其在医药上的应用 |
CN110467638A (zh) * | 2018-05-09 | 2019-11-19 | 北京赛特明强医药科技有限公司 | 一种含有间氯苯胺类取代基的双氨基氯代嘧啶类化合物、制备方法及其应用 |
CN110526941A (zh) * | 2018-05-24 | 2019-12-03 | 北京赛特明强医药科技有限公司 | 一种含有间氯苯胺类取代基的吡咯并嘧啶类化合物、制备方法及其应用 |
CN112313207B (zh) * | 2018-06-22 | 2023-02-14 | 北京赛特明强医药科技有限公司 | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 |
-
2020
- 2020-12-21 AU AU2020414132A patent/AU2020414132B2/en active Active
- 2020-12-21 EP EP20907599.3A patent/EP4083021A4/en active Pending
- 2020-12-21 CA CA3162851A patent/CA3162851A1/en active Pending
- 2020-12-21 US US17/788,663 patent/US20230125046A1/en active Pending
- 2020-12-21 WO PCT/CN2020/137938 patent/WO2021129561A1/zh unknown
- 2020-12-21 CN CN202011516692.7A patent/CN113087671B/zh active Active
- 2020-12-21 KR KR1020227024785A patent/KR20220114643A/ko active Search and Examination
- 2020-12-21 TW TW109145221A patent/TWI781497B/zh active
Also Published As
Publication number | Publication date |
---|---|
JP2023508376A (ja) | 2023-03-02 |
EP4083021A1 (en) | 2022-11-02 |
CN113087671A (zh) | 2021-07-09 |
AU2020414132B2 (en) | 2024-02-15 |
CA3162851A1 (en) | 2021-07-01 |
US20230125046A1 (en) | 2023-04-20 |
EP4083021A4 (en) | 2024-02-07 |
KR20220114643A (ko) | 2022-08-17 |
TW202128646A (zh) | 2021-08-01 |
TWI781497B (zh) | 2022-10-21 |
WO2021129561A1 (zh) | 2021-07-01 |
AU2020414132A1 (en) | 2022-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3181560A1 (en) | Pyridine amidopyrimidine derivative, preparation method and use thereof | |
WO2013170671A1 (zh) | 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用 | |
JP2024505732A (ja) | ピリドピリミジノン系誘導体及びその製造方法と使用 | |
CN111196814B (zh) | 芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用 | |
JP2022502438A (ja) | Fgfr4阻害剤及びその使用 | |
JP2020525469A (ja) | 新規キノリノン化合物 | |
CN112313207B (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
JP7329510B2 (ja) | ピラゾロピリジノン化合物 | |
EP3865488A1 (en) | Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine | |
CN113087671B (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
CN111825719A (zh) | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 | |
CN111836819A (zh) | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 | |
WO2022222871A1 (en) | Heterocyclic compounds as kras g12c inhibitors | |
CN105541792B (zh) | 多环类pi3k抑制剂 | |
JP7491612B2 (ja) | シアノ置換ピリジンおよびシアノ置換ピリミジン系化合物、製造方法およびそれらの使用 | |
CN115894486B (zh) | 一种氢化吡啶并喹唑啉类化合物、组合物及其应用 | |
CN113527215B (zh) | 一种喹唑啉类化合物、制备方法及其应用 | |
WO2022194265A1 (zh) | 一种喹唑啉类化合物、组合物及其应用 | |
TWI820414B (zh) | 喹唑啉類化合物、製備方法及其應用 | |
CN115894455B (zh) | 一种喹唑啉类化合物、组合物及其应用 | |
CN112442045B (zh) | 一种酰基取代的噁嗪并喹唑啉类化合物、制备方法及其应用 | |
CN115894383A (zh) | 一种喹唑啉类化合物、组合物及其应用 | |
CA3188077A1 (en) | Egfr inhibitor, preparation method therefor and application thereof | |
CN115141202A (zh) | 嘧啶并吡嗪酮化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |